Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection

在接种过疫苗的个体中,Omicron 疫苗突破性感染后,针对泛 SARS-CoV-2 变异株的抗体反应增强

阅读:2
作者:Hye Won Jeong,Se-Mi Kim,Min Kyung Jung,Ji Yun Noh,Ji-Seung Yoo,Eun-Ha Kim,Young-Il Kim,Kwangmin Yu,Seung-Gyu Jang,Juryeon Gil,Mark Anthony Casel,Rollon Rare,Jeong Ho Choi,Hee-Sung Kim,Jun Hyoung Kim,Jihye Um,Chaeyoon Kim,Yeonjae Kim,Bum Sik Chin,Sungmin Jung,Jun Yong Choi,Kyoung-Ho Song,Yong-Dae Kim,Jun-Sun Park,Joon Young Song,Eui-Cheol Shin,Young Ki Choi

Abstract

Omicron has become the globally dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, creating additional challenges due to its ability to evade neutralization. Here, we report that neutralizing antibodies against Omicron variants are undetected following COVID-19 infection with ancestral or past SARS-CoV-2 variant viruses or after two-dose mRNA vaccination. Compared with two-dose vaccination, a three-dose vaccination course induces broad neutralizing antibody responses with improved durability against different SARS-CoV-2 variants, although neutralizing antibody titers against Omicron remain low. Intriguingly, among individuals with three-dose vaccination, Omicron breakthrough infection substantially augments serum neutralizing activity against a broad spectrum of SARS-CoV-2 variants, including Omicron variants BA.1, BA.2, and BA.5. Additionally, after Omicron breakthrough infection, memory T cells respond to the spike proteins of both ancestral and Omicron SARS-CoV-2 by producing cytokines with polyfunctionality. These results suggest that Omicron breakthrough infection following three-dose mRNA vaccination induces pan-SARS-CoV-2 immunity that may protect against emerging SARS-CoV-2 variants of concern.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。